Nektar Therapeutics (NASDAQ:NKTR)
| 18.86 Delayed Data As of May 13 |  +0.29 / +1.56%Today’s Change | 15.40 Today|||52-Week Range 26.75 | +10.94% Year-to-Date |
Latest NKTR News | Press Releases
| Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last? May 10 / Zacks.com - Paid Partner Content | Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates May 06 / Zacks.com - Paid Partner Content |
| Nektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript May 07 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 18.57 |
| Today’s open | 19.33 |
| Day’s range | 18.36 - 18.99 |
| Volume | 44,739 |
| Average volume (3 months) | 1,178,061 |
| Market cap | $3.7B |
Data as of 4:00pm ET, 05/13/2021
Growth & Valuation
| Earnings growth (last year) | +1.17% |
| Earnings growth (this year) | -20.88% |
| Earnings growth (next 5 years) | -28.00% |
| Revenue growth (last year) | +33.41% |
| P/E ratio | NM |
| Price/Sales | 19.85 |
| Price/Book | 3.36 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| EBSEmergent BioSolution... | -0.08 | -0.14% |
| ALLOAllogene Therapeutic... | -1.00 | -3.58% |
| ARVNArvinas Inc | +0.69 | +1.10% |
| IOVAIovance Biotherapeut... | -1.06 | -4.06% |
Data as of 4:00pm ET, 05/13/2021
Financials
| Next reporting date | August 12, 2021 |
| EPS forecast (this quarter) | -$0.74 |
| Annual revenue (last year) | $152.9M |
| Annual profit (last year) | -$444.4M |
| Net profit margin | -290.65% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Francisco, California |
Forecasts
